share_log

Piper Sandler Maintains Overweight on Moderna, Lowers Price Target to $115

Benzinga ·  Sep 13 18:59  · Ratings

Piper Sandler analyst Edward Tenthoff maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $157 to $115.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment